The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience.
Publication/Presentation Date
1-1-1995
Abstract
Tacrolimus is a superior immunosuppressive agent in patients undergoing renal transplantation. In adults, the 1- and 3-year actuarial patient survivals were 95% and 92%, and the 1- and 3-year actuarial graft survivals were 89% and 80%. For first cadaver kidneys, the 1- and 3-year actuarial graft survivals were 91% and 82%, with a projected half-life of 11.9 years. Sixty-nine percent of successfully transplanted patients were weaned off steroids. In pediatric patients, the 1- and 4-year actuarial patient survivals were 100% and 96%, and the 1- and 4-year actuarial graft survivals were 99% and 85%. Seventy-three percent of successfully transplanted children were weaned off steroids. Tacrolimus was also useful as a rescue agent, with an initial success rate of 74%. Tacrolimus has been used successfully in kidney/ pancreas transplantation, with 100% patient, 95% kidney, and 79% pancreas graft survival. Tacrolimus should be considered the immunosuppressive agent of choice in renal transplantation.
First Page
199
Last Page
205
ISSN
0890-9016
Published In/Presented At
Shapiro, R., Jordan, M. L., Scantlebury, V. P., Vivas, C., Gritsch, H. A., Corry, R. J., Egidi, F., McCauley, J., Ellis, D., & Gilboa, N. (1995). The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clinical transplants, 199–205.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
8794266
Department(s)
Administration and Leadership
Document Type
Article